Harnessing Endogenous Ligases to Expand the Reach of Molecular Glue Degradation

• Developing molecular glue degraders that leverage endogenous ligases beyond cereblon, expanding the range of induced-proximity mechanisms available for targeted protein degradation
• Applying novel ligase biology to challenging targets including KRAS and SREBF, unlocking therapeutic opportunities against proteins that have traditionally proven difficult to drug
• Establishing a new framework for molecular glue discovery beyond cereblon-dependent approaches, broadening the degrader toolbox and enabling the next generation of targeted therapies

Speakers:

Anita Bellail

Chief Executive Officer

HB Therapeutics, Inc.